ExploreWatchlistsPricing
  1. JP-listed companies
  2. Eisai Co., Ltd.
  3. Financials
  4. EBITDA

Eisai Co., Ltd. (4523)

Market cap
¥1.43T
P/E ratio
33.2x
Eisai develops, manufactures and sells prescription drugs and over-the-counter medicines globally across Japan, North America, China, Europe and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 202594,284+1.59%
Mar 31, 202492,806+15.98%
Mar 31, 202380,021-13.16%
Mar 31, 202292,148+4.64%
Mar 31, 202188,065-44.68%
Mar 31, 2020159,202+40.89%
Mar 31, 2019112,995+66.23%
Mar 31, 201867,977

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat